Grosicki Sebastian, Barchnicka Agnieszka, Jurczyszyn Artur, Grosicka Anida
Department of Hematology, Community Hospital in Chorzow, Chorzow, Poland.
Expert Rev Hematol. 2014 Apr;7(2):173-85. doi: 10.1586/17474086.2014.899144.
Bortezomib is the first proteasome inhibitor drug tested in human patients. Bortezomib demonstrates a particular clinical utility in the treatment of multiple myeloma (MM), where it is the only one of the new drugs administered as mono-therapy that prolongs survival. The significant problem for the consistent pursuit of bortezomib was neurotoxicity, which has been significantly reduced by registering subcutaneous administration or being administered once per week. Bortezomib is currently approved for the treatment of patients with progressive MM in mono-therapy and in combination with prednisone and melphalan in cases of untreated patients who are not candidates for autologous hematopoietic stem cell transplantation (AHSCT) and in combination with dexamethasone or dexamethasone and thalidomide in untreated MM patients, who are candidates for treatment AHSCT. Clinical research is focused on the combination of bortezomib with other new drugs with the hope of further optimizing the treatment of patients with multiple myeloma.
硼替佐米是首个在人类患者中进行测试的蛋白酶体抑制剂药物。硼替佐米在治疗多发性骨髓瘤（MM）方面显示出特殊的临床效用，它是唯一一种作为单一疗法使用且能延长生存期的新药。持续使用硼替佐米的一个重大问题是神经毒性，通过采用皮下给药或每周给药一次，神经毒性已显著降低。目前，硼替佐米被批准用于单一疗法治疗进展性MM患者，对于不适合进行自体造血干细胞移植（AHSCT）的未治疗患者，可与泼尼松和马法兰联合使用；对于适合AHSCT治疗的未治疗MM患者，可与地塞米松或地塞米松和沙利度胺联合使用。临床研究聚焦于硼替佐米与其他新药的联合使用，以期进一步优化多发性骨髓瘤患者的治疗。
